Compare PayPal Holdings, Inc. (PYPL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PayPal Holdings, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? PayPal Holdings, Inc. trades at $55.52 (market cap $49.27B), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.5× PayPal Holdings, Inc.'s market cap, and PayPal Holdings, Inc. pays a 1% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| PYPL | VRTX | |
|---|---|---|
Market Cap | $49.27B | $122.33B |
Sector | Financials | Health |
52-Week High | $78.22 | $529.59 |
52-Week Low | $39.08 | $366.54 |
Enterprise Value | $49.33B | $117.07B |
Dividend Yield | 1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PayPal (PYPL) trades at $55.85, down 1.26% today, amid takeover speculation from Stripe and Advent International. The stock shows strong fundamentals with a P/E of 10.66 and net income margin of 15%, while technical indicators are mixed with a bullish moving average signal but overbought RSI levels. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow from operations of $6.42 billion in 2025.
The outlook is clouded by the potential buyout, which could limit upside if the offer is rejected, while profitability pressures and competition from Apple Pay pose risks. Analyst consensus is cautious with a hold-heavy rating, suggesting investors await clarity on strategic direction amid the takeover bid.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
